Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The therapeutic age of the neonatal Fc receptor
Michał Pyzik, Lisa K. Kozicky, Amit Gandhi, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 7, pp. 415-432
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 131
Extracellular targeted protein degradation: an emerging modality for drug discovery
James A. Wells, Kaan Kumru
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 2, pp. 126-140
Closed Access | Times Cited: 65
Engineering the IL‐4/IL‐13 axis for targeted immune modulation
Zachary J. Bernstein, Anjali Shenoy, Amy Chen, et al.
Immunological Reviews (2023) Vol. 320, Iss. 1, pp. 29-57
Open Access | Times Cited: 43
Myasthenia gravis: the changing treatment landscape in the era of molecular therapies
Raffaele Iorio
Nature Reviews Neurology (2024) Vol. 20, Iss. 2, pp. 84-98
Closed Access | Times Cited: 35
Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties
Nilufer P. Seth, Rui Xu, Matthew DuPrie, et al.
mAbs (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 3
Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain
Nathan T. Fiore, Kendal F. Willcox, Dorsa Dayani, et al.
Brain Behavior and Immunity (2025)
Open Access | Times Cited: 2
Batoclimab vs Placebo for Generalized Myasthenia Gravis
Chong Yan, Yao-Xian Yue, Yuzhou Guan, et al.
JAMA Neurology (2024) Vol. 81, Iss. 4, pp. 336-336
Closed Access | Times Cited: 12
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)
James F. Howard, Tuan Vu, George Li, et al.
Neurotherapeutics (2024) Vol. 21, Iss. 5, pp. e00378-e00378
Closed Access | Times Cited: 12
Structure and function of therapeutic antibodies approved by the US FDA in 2023
William R. Strohl
Antibody Therapeutics (2024) Vol. 7, Iss. 2, pp. 132-156
Open Access | Times Cited: 9
Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report
Huasheng Huang, Yizhi Wei, HuiHui Qin, et al.
BMC Neurology (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
Alberto L. Horenstein, Angelo Corso Faini, Fabio Morandi, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Small RNA and Toll-like receptor interactions: origins and disease mechanisms
Jiancheng Yu, Xu Dong Zhang, Chen Cai, et al.
Trends in Biochemical Sciences (2025)
Closed Access | Times Cited: 1
Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin
Guanglong Ma, Andrew R. Crowley, Liesbeth Heyndrickx, et al.
JCI Insight (2024) Vol. 9, Iss. 10
Open Access | Times Cited: 7
Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study
Jocelyn H. Leu, An Vermeulen, Claudia Abbes, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 6
Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis
Paola Cavalcante, Renato Mantegazza, Carlo Antozzi
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Inflammation-Targeted Drug Delivery Strategies via Albumin-Based Systems
Bangqing Wu, Jingwen Wang, Yi Chen, et al.
ACS Biomaterials Science & Engineering (2024) Vol. 10, Iss. 2, pp. 743-761
Closed Access | Times Cited: 5
Beyond nanoparticle-based oral drug delivery: transporter-mediated absorption and disease targeting
Hana Cho, Kang Moo Huh, Hyun Ji Cho, et al.
Biomaterials Science (2024) Vol. 12, Iss. 12, pp. 3045-3067
Open Access | Times Cited: 5
Robust Prediction of Relative Binding Energies for Protein–Protein Complex Mutations Using Free Energy Perturbation Calculations
Jared M. Sampson, Daniel A. Cannon, Jian‐Xin Duan, et al.
Journal of Molecular Biology (2024) Vol. 436, Iss. 16, pp. 168640-168640
Open Access | Times Cited: 5
Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report
Shiqi Huang, Zhenhua Yuan, Hong Ye, et al.
Neurological Sciences (2024) Vol. 45, Iss. 11, pp. 5511-5515
Closed Access | Times Cited: 5
Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series
Jie Song, Haiyan Wang, Xiao Huan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Bullous pemphigoid induced by IgG targeting type XVII collagen non‐NC16A/NC15A extracellular domains is driven by Fc gamma receptor‐ and complement‐mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade
Manuela Pigors, Sabrina Patzelt, Niklas Reichhelm, et al.
The Journal of Pathology (2023) Vol. 262, Iss. 2, pp. 161-174
Open Access | Times Cited: 12
FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines
Christophe Macri, Matthew Paxman, Devi Jenika, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Case report: Rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series
Qianqian Zhang, Wenping Yang, Yun Qian, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Fc Gamma Receptor Polymorphisms in Antibody Therapy: Implications for Bioassay Development to Enhance Product Quality
Julianne D. Twomey, S. Elizabeth George, Bao-Lin Zhang
Antibody Therapeutics (2025) Vol. 8, Iss. 2, pp. 87-98
Open Access
Therapies for myasthenia gravis: FcRn inhibition and beyond
Christiane Schneider‐Gold, Ralf Gold
The Lancet Neurology (2025) Vol. 24, Iss. 2, pp. 88-89
Closed Access
Page 1 - Next Page

Scroll to top